Femasys (FEMY) Stock

Company accelerated commercialization with significant new partnerships both in the U.S. and Europe Company accelerated commercialization with significant new partnerships both in the U.S. and Europe

FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control

Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council

ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribution partners after successfully completing its first commercial FemaSeed® procedures in Europe. Members of the Femasys team traveled to Madrid to in-service healthcare practitioners on the innovative FemaSeed infertility treatment, designed to enhance natural fertilization by precisely delivering sperm into the fallopian tube where conception occurs.

Leading medical clinics become key regional resources to offer FemaSeed infertility treatment Leading medical clinics become key regional resources to offer FemaSeed infertility treatment

Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products

FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.

In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial

ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the Canadian Fertility and Andrology Society's (CFAS) 70th Annual Meeting, to be held September 12-14, 2024 at The Westin Bayshore, Vancouver, British Columbia. The Company will be exhibiting at Booth #S26.